UB Paderborn / Katalog / Suche / in CDI

1 – 17 von 17

Sortiert nach

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Journal of thoracic oncology, 2023-05, Vol.18 (5), p.576-586

2023

Volltextzugriff (PDF)

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

Journal of clinical oncology, 2017-05, Vol.35 (13), p.1403-1410

2017

Volltextzugriff (PDF)

Development of a ‘ready-to-use’ tool that includes preventability, for the assessment of adverse drug events in oncology

International journal of clinical pharmacy, 2018-04, Vol.40 (2), p.376-385

2018

Volltextzugriff (PDF)

Complementary medicines in oncology

Atención primaria, 2007-01, Vol.39 (1), p.5-6

2007

Volltextzugriff (PDF)

Discontinuation of immunotherapy over 2 years for patients with non–small cell lung cancer (NSCLC): A search for predictors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2661-2661

2023

Volltextzugriff (PDF)

A phase II study of alectinib in combination with bevacizumab as first-line treatment in advanced NSCLC with confirmed ALK fusion: ALEK-B trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9074-9074

2022

Volltextzugriff (PDF)

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Science (American Association for the Advancement of Science), 2018-01, Vol.359 (6371), p.91-97

2018

Volltextzugriff (PDF)

18F-FDG PET–derived parameter total lesion glycolisis (TLG) as a tool to stratify patients (pts) with advanced non–small cell lung cancer (aNSCLC) treated with immunotherapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9062-9062

2022

Volltextzugriff (PDF)

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Journal of thoracic oncology, 2023-05, Vol.18 (5), p.576-586

2023

Volltextzugriff (PDF)

Prediction of the molecular status in non-small cell lung cancer based on metastatic pattern: A free webtool powered by artificial intelligence

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9535-9535

2020

Volltextzugriff (PDF)

Abstract 559: Expression of molecular targets for antibody-drug conjugates in patients with NSCLC and RET fusions

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.559-559

2023

Volltextzugriff (PDF)

Abstract 856: Number of ALK-amplified circulating tumor cells predicts progression-free survival in ALK-rearranged non-small cell lung cancer patients treated by crizotinib

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.856-856

2016

Volltextzugriff (PDF)

Abstract B7: Assessing the clinical applications of ctDNA in patients with advanced stage metastatic cancer using our enhanced TAm-Seq platform

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B7-B7

2015

Volltextzugriff (PDF)

Thymoma and thymic carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations

Pediatric blood & cancer, 2021-06, Vol.68 (S4), p.e29042-n/a

2021

Volltextzugriff (PDF)

Medicinas complementarias en oncología

Atención primaria, 2007, Vol.39 (1), p.5-6

2007

Volltextzugriff (PDF)

Medicinas complementarias en oncología

Atención primaria, 2007-01, Vol.39 (1), p.5-6

2007

Volltextzugriff (PDF)

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications

The Journal of Liquid Biopsy, 2023-09, Vol.1, p.100007, Article 100007

2023

Volltextzugriff (PDF)

1 – 17 von 17

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(17)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

Development of a ‘ready-to-use’ tool that includes preventability, for the assessment of adverse drug events in oncology

Complementary medicines in oncology

Discontinuation of immunotherapy over 2 years for patients with non–small cell lung cancer (NSCLC): A search for predictors

A phase II study of alectinib in combination with bevacizumab as first-line treatment in advanced NSCLC with confirmed ALK fusion: ALEK-B trial

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

18F-FDG PET–derived parameter total lesion glycolisis (TLG) as a tool to stratify patients (pts) with advanced non–small cell lung cancer (aNSCLC) treated with immunotherapy

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Prediction of the molecular status in non-small cell lung cancer based on metastatic pattern: A free webtool powered by artificial intelligence

Abstract 559: Expression of molecular targets for antibody-drug conjugates in patients with NSCLC and RET fusions

Abstract 856: Number of ALK-amplified circulating tumor cells predicts progression-free survival in ALK-rearranged non-small cell lung cancer patients treated by crizotinib

Abstract B7: Assessing the clinical applications of ctDNA in patients with advanced stage metastatic cancer using our enhanced TAm-Seq platform

Thymoma and thymic carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations

Medicinas complementarias en oncología

Medicinas complementarias en oncología

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications

Suchergebnisse filtern